...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 and Enzalutamide 2b Trial - Astella owns a piece of Xtandi (aka Enzalutamide)

fun fact:  Talked with a fella that did a PP for $2US couple years back with a fairly tale ending of June 2019 - now he watches it trade for around .40US cents & could puke. Wonder how the koolaid is tasting now with more of the same? This is a R & D company being played by big pharma IMO & this will go on for several more years.

Thank donny when ya see him for all of his hard work, excitment & increased shareholder value that he has brought to all of us. Pathetic!

Share
New Message
Please login to post a reply